Adding a variant: the test in FDA's draft
Individualized human genome editing products. CBER draft guidance, October 2026.
Step 1
Inside the feature space?
Step 2
Safety and activity predicted?
If both hold
A manufacturing change
Scope: all three required
1. A monogenic disease
2. Known pathogenic variants
3. The same editing outcome across all variants
Adding a variant
A BLA supplement with in vitro activity at or above a clinical threshold, plus in vitro safety data
Outside the box
Expanding the space: a prior approval supplement.
A fundamental design change or new risk: a new BLA.
This is a nonbinding draft marked not for implementation. The final guidance may differ.
Summary of FDA’s October 2026 draft guidance.
FDA’s new draft treats some new gene editing variants as manufacturing changes, not new products.
It applies only inside a narrow, pre-defined box.
On October 27, 2026, HHS announced a CBER draft guidance on individualized genome editing products. A new variant inside an established feature space can be added without new clinical trials if three scope conditions are met and the lab-to-clinic link is well understood. The draft is nonbinding and still open for comment.
What FDA announced
On October 27, 2026, HHS announced new steps by FDA and CMS on gene therapies for rare diseases. One is a draft guidance from FDA’s Center for Biologics Evaluation and Research (CBER), titled Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management.
The document is marked “Draft – Not for Implementation” and is nonbinding. HHS says comments go to docket FDA-2026-D-11783 at regulations.gov within 30 days of Federal Register publication. The exact closing date depends on that publication, so check the Federal Register notice before planning a submission.
In the same announcement, CMS said it will broaden its CGT Access Model beyond sickle cell disease and release a Request for Applications in the coming months.
BioPharma Dive reported that TD Cowen analyst Joseph Thome called the approach “plug and play” optionality. It also reported that Prime Medicine shares jumped 15% early Wednesday and Beam Therapeutics shares rose 8%.
In FDA’s draft, a new variant inside the established feature space, with adequate predicted safety and activity, is a manufacturing change, not a new product.
Who qualifies
The draft applies only when all three of these conditions hold.
All three must hold
The draft does not cover clinical study design, non-individualized genome editing products or specific approval pathways. The HHS announcement describes it as a proposal for personalized gene therapies, but the guidance text itself covers individualized genome editing products only.
How the feature space works
The key term is the individualized feature space (IFS), defined as the allowable limits of variation for the variable features of the genome editing components. A sponsor establishes it with clinical data plus in vitro criteria, such as acceptable off-target editing and a minimum on-target editing criterion.
A new variant is a manufacturing change rather than a new product if two things hold. Its variable features sit within the established IFS, and it is predicted to have adequate safety and activity from clinical or in vitro data.
Some features must stay constant across variants: strength, formulation, the delivery vehicle or vector, and the cell type for ex vivo products.
The same mechanism of action applies across a BLA. A base editor may be grouped with PAM-variant base editors. A reverse-transcriptase-based editor on an adenine base editor product would need a new BLA.
FDA’s Table 1 gives an example IFS for an adenine base editor, with a rule-based guide RNA (gRNA) and a menu-based editor. Adding a gRNA within the IFS is an addition within the established IFS, while adding a new editor is an IFS expansion.
FDA encourages sponsors to develop the IFS prospectively and to discuss it with FDA before pivotal studies.
What evidence FDA expects
In an initial BLA, variants that were not clinically evaluated may be listed if they meet the in vitro criteria and the clinical evidence spans the IFS. FDA says extrapolation is case by case, weighing natural history and genotype-phenotype knowledge, genotype factors such as immunogenicity, remaining uncertainties and the link between in vitro and clinical results. A gRNA that fails the criteria needs additional clinical data.
To add a variant later, a sponsor files a BLA supplement under 21 CFR 601.12(a)(2). It needs in vitro activity at or above a clinically established threshold plus in vitro safety data. FDA “generally does not expect clinical data” there if the link between in vitro data and clinical results is well understood and predictable.
Otherwise, clinical data from subjects who received that variant are needed.
Expanding the IFS in an approved BLA is a prior approval supplement under 21 CFR 601.12. In certain circumstances in vitro studies may suffice. FDA would not expect clinical data for a new editor with conservative PAM-recognition changes if the effects are well understood and predictable.
A fundamental design change or significant new or unknown risks needs a new BLA.
FDA recommends a postapproval change management protocol (PACMP) under 21 CFR 601.12(e) for these changes.
The “no clinical data” path depends on a well-understood link between in vitro data and clinical results.
Manufacturing, safety and labeling
The draft also sets expectations beyond clinical data, summarized below from the guidance text.
CMC, safety and labeling in the draft
- Process: manufacturing should be robust across the IFS, with no per-variant revalidation. Process performance qualification is risk-based and brackets the scale extremes.
- Identity and purity: identity per 21 CFR 610.14, including sequencing the gRNA spacer for in vivo products, and chain of identity for ex vivo products. Purity per 21 CFR 610.13.
- Potency: a criterion based on clinical data, possibly relative to a reference material, and possibly needing potency cell lines that carry the targeted variants.
- Safety: a per-variant in vitro off-target assessment using pre-defined NGS-based methods, with the protocol submitted in the BLA.
- Added variants: representative or scaled-down components are acceptable if purity, chemistry and structure are equivalent, and CGMP applies to commercial lots.
- Labeling: indications reflect the disease and the variants shown safe and effective. Names do not distinguish variants, there is no separate NDC per variant, and the label carries the lot number plus a variant identifier such as “Targeted gene variant: [xxxxx]”.
A variant tied to a clinically distinct disease in the same gene is a new indication and needs clinical evidence.
What this means for a CGT program
GTC analysis: the draft appears to matter most for a sponsor that expects to add several variants under one BLA after approval. A program built around a single product has little to gain from a feature space. For a platform, the value grows with each planned variant, which is why FDA encourages agreeing the feature space before pivotal studies.
GTC analysis: if you run a base or prime editing platform, the CMC work moves into your first BLA. A potency criterion tied to clinical data, a per-variant off-target method and a process that holds across the whole feature space all need to be settled up front. Do not leave them to be worked out variant by variant later.
GTC analysis: plan budget and timeline on the conservative case. The draft is nonbinding, the no-clinical-data path is conditional, and the final text may differ. A program outside the three scope conditions, such as one with different editing outcomes per patient, should not assume it applies.
GTC analysis: payment is a separate question. CMS’s planned expansion of its CGT Access Model is the payment-side step in the same announcement, and Beam CEO John Evans raised on X whether one-time prices become a roadblock.
If you have built the CMC or potency package for a genome editing product, the GTC Expert Network matches people with that experience to paid consulting work: join free.
Frequently asked questions
What does FDA’s draft guidance on individualized genome editing products cover?
It covers products intended to prevent, treat or cure a monogenic disease caused by known pathogenic gene variants. All product variants in the BLA must be designed to achieve the same editing outcome, and all three conditions must hold. The draft excludes clinical study design, non-individualized genome editing products and specific approval pathways.
Does adding a new variant need new clinical trials under the draft?
Not always. FDA generally does not expect clinical data when adding a variant if the in vitro-to-clinical link is well understood and predictable. Otherwise, clinical data from subjects who received that variant are needed.
What is an individualized feature space?
It is the allowable limits of variation for the variable features of the genome editing components. A new variant is a manufacturing change rather than a new product in two cases. Its variable features must sit within the established feature space, and it must be predicted to have adequate safety and activity.
Is the guidance final, and when are comments due?
No. It is a CBER draft marked as not for implementation, and it is nonbinding. HHS says comments go to docket FDA-2026-D-11783 within 30 days of Federal Register publication.
Does this cover all personalized or rare disease gene therapies?
No. The guidance text covers individualized human genome editing products only. The HHS announcement describes it as a proposal for personalized gene therapies, but the scope conditions in the draft are narrower.
Sources
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management - U.S. Food and Drug Administration, CBER, draft guidance, October 2026. Source for the scope conditions, the feature space, the evidence expectations, the manufacturing and labeling points.
- FDA and CMS Announce New Steps to Advance Gene Therapies and Expand Access for Patients with Rare Diseases - U.S. Department of Health and Human Services, press release, October 27, 2026. Source for the announcement, docket FDA-2026-D-11783, the 30-day comment period and the CMS CGT Access Model expansion.
- FDA unveils guidance for ‘plug and play’ gene therapies - BioPharma Dive, Kristin Jensen, October 28, 2026. Source for the analyst comment, the share moves and the Beam CEO comment.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.